A data-forward reading of the CJC-1295 + ipamorelin literature — what the GH/IGF-1 numbers actually show, and what the fixed blend has never been tested for.
CJC-Ipa Research

THE LITERATURE // SOURCED LINE BY LINE

CJC-1295 Ipamorelin References

Every quantitative claim on this site maps to one of these studies. DOIs and PubMed identifiers included.

Back to the researchReported effects

How to read this list

These are the primary sources behind the CJC-1295 Ipamorelin claims across this site, numbered to match the inline [N] markers. Studies on the single components and on GHRH-plus-GHRP synergy carry the weight; there is no entry for a trial of the fixed blend because none exists. Human studies, animal studies, in-vitro work, and authoritative statements are all flagged in each citation.

  1. Teichman SL, Ferris L, Mooradian AD, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. (Human; healthy adults) ↗
  2. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. (Animal; rat pituitary cells and conscious swine) ↗
  3. Bowers CY, Reynolds GA, Durham D, et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-982. (Human; 18 normal men) ↗
  4. Cunha SR, Mayo KE. Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3',5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology. 2002;143(12):4570-4582. (In vitro; transfected HeLa cells) ↗
  5. Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. (Animal; Sprague-Dawley rats) ↗
  6. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. (Human; review of multiple trials) ↗
  7. Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20(1):2-12. (Human; meta-analysis of 5 RCTs) ↗
  8. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. (Human; healthy men 20-40 yr) ↗
  9. Stanley TL, Chen CY, Branch KL, et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-158. (Human; 13 healthy men) ↗
  10. Chapman IM, Bach MA, Van Cauter E, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab. 1996;81(12):4249-4257. (Human; 32 healthy elderly subjects) ↗
  11. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. (Human; healthy young men) ↗
  12. Cappola AR, Auchus RJ, El-Hajj Fuleihan G, et al. Hormones and Aging: An Endocrine Society Scientific Statement. J Clin Endocrinol Metab. 2023;108(8):1835-1874. (Human; scientific statement) ↗
  13. Growth hormone-releasing factor-sensitive adenylate cyclase system of purified somatotrophs. 1989. (In vitro; ovine pituitary somatotrophs) ↗
  14. Frohman LA, Downs TR, Heimer EP, Felix AM. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest. 1989;83(5):1533-1540. (In vitro; human plasma) ↗
  15. Pharmacokinetics of growth hormone releasing factor [GRF(1-29)NH2] in normal men. 1986. (Human; healthy men) ↗